Gilead wins a blockbuster consolation prize with EC, Japanese approvals for filgotinib — but that barely softens the blow of the FDA's CRL

John Carroll

Editor & Founder

The FDA’s recent slapdown of Gilead’s rheumatoid arthritis JAK filgotinib didn’t even slightly delay its arrival in 2 big world markets. The EC stamped its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gilead wins a blockbuster consolation prize with EC, Japanese approvals for filgotinib — but that barely softens the blow of the FDA's CRL

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

GSK defiant against vaccine challenges, will prioritize other growth areas

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

Novo Nordisk sees growth slowing this year, plans CagriSema filing for 2026

New study will try to stop Alzheimer’s decades before it begins, using experimental Eli Lilly drug

Drugmakers seize on biomarkers to test the FDA's rare disease shift

Gilead wins a block­buster con­so­la­tion prize with EC, Japan­ese ap­provals for fil­go­tinib — but that bare­ly soft­ens the blow of the FDA's CRL

Editor & Founder

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Gilead wins a blockbuster consolation prize with EC, Japanese approvals for filgotinib — but that barely softens the blow of the FDA's CRL